
Brian J. Davis
Examiner (ID: 8682, Phone: (571)272-0638 , Office: P/1672 )
| Most Active Art Unit | 1621 |
| Art Unit(s) | 1621, 1627, 1672, 1614, 1615, 1612 |
| Total Applications | 2900 |
| Issued Applications | 2335 |
| Pending Applications | 201 |
| Abandoned Applications | 384 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20701341
[patent_doc_number] => 12624041
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-12
[patent_title] => Heterocyclic compound and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/014143
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 23255
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1891
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014143
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/014143 | Heterocyclic compound and use thereof | Jun 22, 2021 | Issued |
Array
(
[id] => 17334490
[patent_doc_number] => 20220000821
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => Diagnostic Assay and Treatment for Preeclampsia
[patent_app_type] => utility
[patent_app_number] => 17/348942
[patent_app_country] => US
[patent_app_date] => 2021-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9634
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17348942
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/348942 | Diagnostic assay and treatment for preeclampsia | Jun 15, 2021 | Issued |
Array
(
[id] => 17124371
[patent_doc_number] => 20210299139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => METHODS AND COMPOSITIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS
[patent_app_type] => utility
[patent_app_number] => 17/341916
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36228
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17341916
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/341916 | Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids | Jun 7, 2021 | Issued |
Array
(
[id] => 18649326
[patent_doc_number] => 20230295115
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/008873
[patent_app_country] => US
[patent_app_date] => 2021-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46892
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18008873
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/008873 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Jun 6, 2021 | Abandoned |
Array
(
[id] => 17212971
[patent_doc_number] => 20210346307
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/339563
[patent_app_country] => US
[patent_app_date] => 2021-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11600
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339563
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/339563 | Synthetic lipid-like materials for brain delivery | Jun 3, 2021 | Issued |
Array
(
[id] => 18341232
[patent_doc_number] => 11638700
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-02
[patent_title] => Iron/shikonin nano-composite and use thereof and method for preparing the same by supermolecular self-assembly
[patent_app_type] => utility
[patent_app_number] => 17/335565
[patent_app_country] => US
[patent_app_date] => 2021-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 3157
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17335565
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/335565 | Iron/shikonin nano-composite and use thereof and method for preparing the same by supermolecular self-assembly | May 31, 2021 | Issued |
Array
(
[id] => 18582850
[patent_doc_number] => 20230265105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
[patent_app_type] => utility
[patent_app_number] => 17/998957
[patent_app_country] => US
[patent_app_date] => 2021-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35716
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998957
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998957 | MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | May 26, 2021 | Abandoned |
Array
(
[id] => 18537738
[patent_doc_number] => 20230242838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => PREVENTION OF MCPD FORMATION BY HIGH TEMPERATURE WASHING
[patent_app_type] => utility
[patent_app_number] => 17/999723
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999723
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999723 | PREVENTION OF MCPD FORMATION BY HIGH TEMPERATURE WASHING | May 25, 2021 | Pending |
Array
(
[id] => 19011673
[patent_doc_number] => 11918574
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => Method of treating cancer associated with a RAS mutation
[patent_app_type] => utility
[patent_app_number] => 17/328091
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 11777
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328091
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/328091 | Method of treating cancer associated with a RAS mutation | May 23, 2021 | Issued |
Array
(
[id] => 20664778
[patent_doc_number] => 12606540
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-21
[patent_title] => Triazolone compound
[patent_app_type] => utility
[patent_app_number] => 17/999557
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 25
[patent_no_of_words] => 18518
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999557
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999557 | Triazolone compound | May 23, 2021 | Issued |
Array
(
[id] => 17081989
[patent_doc_number] => 20210276995
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/326159
[patent_app_country] => US
[patent_app_date] => 2021-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19101
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17326159
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/326159 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | May 19, 2021 | Issued |
Array
(
[id] => 17126137
[patent_doc_number] => 20210300905
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR)
[patent_app_type] => utility
[patent_app_number] => 17/314753
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314753
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/314753 | Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) | May 6, 2021 | Issued |
Array
(
[id] => 17458707
[patent_doc_number] => 20220072011
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/245216
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22285
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245216
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/245216 | TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF | Apr 29, 2021 | Abandoned |
Array
(
[id] => 17343580
[patent_doc_number] => 20220009911
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => INHIBITORS OF CXCR2
[patent_app_type] => utility
[patent_app_number] => 17/243872
[patent_app_country] => US
[patent_app_date] => 2021-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243872
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/243872 | Inhibitors of CXCR2 | Apr 28, 2021 | Issued |
Array
(
[id] => 17198556
[patent_doc_number] => 20210338650
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => CXCL10 Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/242867
[patent_app_country] => US
[patent_app_date] => 2021-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12119
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 277
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17242867
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/242867 | CXCL10 Inhibitors | Apr 27, 2021 | Abandoned |
Array
(
[id] => 18420084
[patent_doc_number] => 20230174545
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/921939
[patent_app_country] => US
[patent_app_date] => 2021-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20878
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 726
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17921939
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/921939 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | Apr 27, 2021 | Abandoned |
Array
(
[id] => 17193092
[patent_doc_number] => 11161833
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-11-02
[patent_title] => Deuterated etoricoxib, methods of manufacture, and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/240446
[patent_app_country] => US
[patent_app_date] => 2021-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 50249
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240446
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/240446 | Deuterated etoricoxib, methods of manufacture, and use thereof | Apr 25, 2021 | Issued |
Array
(
[id] => 19012924
[patent_doc_number] => 11919839
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-05
[patent_title] => Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/238529
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46967
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17238529
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/238529 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | Apr 22, 2021 | Issued |
Array
(
[id] => 17460183
[patent_doc_number] => 20220073488
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => COMPOSITIONS COMPRISING AN UROLITHIN COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/238525
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9103
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17238525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/238525 | Compositions comprising an urolithin compound | Apr 22, 2021 | Issued |
Array
(
[id] => 17183819
[patent_doc_number] => 20210330704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => Nasal Spray Composition
[patent_app_type] => utility
[patent_app_number] => 17/237497
[patent_app_country] => US
[patent_app_date] => 2021-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6428
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17237497
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/237497 | Nasal spray composition | Apr 21, 2021 | Issued |